Isoptin

Verapamil Hydrochloride, the active ingredient in Isoptin, is a calcium channel blocker presented as an intravenous solution for intravenous use. It reduces blood pressure, relieves chest pain from angina, and helps control supraventricular tachyarrhythmias such as atrial fibrillation in adult patients.

GNH USA supplies Isoptin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, including Europe, Asia and the Americas, ensuring quality and regulatory conformity for global distribution. The company provides reliable logistics, regulatory support and documentation to facilitate import and clinical use.

Isoptin (verapamil hydrochloride) acts on calcium channels to manage cardiovascular conditions.

- Hypertension: lowers systemic blood pressure by vasodilation. - Angina pectoris: reduces myocardial oxygen demand and improves coronary blood flow. - Supraventricular tachyarrhythmias: slows atrioventricular conduction to control heart rate in atrial fibrillation or flutter.

Adverse reactions may occur with intravenous verapamil administration.

Common Side Effects: - Headache: mild to moderate pain in the head. - Flushing: sensation of warmth and redness. - Dizziness: light‑headed feeling. - Nausea: upset stomach.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Bradycardia: abnormally slow heart rate. - Heart block: impaired electrical conduction.

Careful monitoring is required when using Isoptin.

- Monitor blood pressure: check regularly during therapy. - Assess cardiac function: ECG monitoring for conduction changes. - Adjust dose in hepatic impairment: reduce dosage if liver function is compromised. - Caution in patients with heart failure: may worsen condition. - Avoid concomitant use with strong CYP3A4 inhibitors: may increase plasma levels. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Verapamil has several notable drug interactions.

Major Interactions (Avoid): - Concurrent use with beta‑blockers: risk of excessive bradycardia. - Combination with digoxin: increased risk of toxicity. - Co‑administration with strong CYP3A4 inhibitors (e.g., ketoconazole): may cause severe hypotension.

Moderate Interactions (Monitor Closely): - Use with diltiazem: additive AV‑node effects. - Interaction with statins metabolized by CYP3A4: may raise statin levels. - Concomitant use with diuretics: may enhance hypotensive effect.